Trial Profile
An Open-Label Study to Evaluate the Pharmacokinetic and Pharmacodynamic Response of a Hydrated and Non-Hydrated 84mg Octreotide Implant in Patients With Acromegaly
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Octreotide (Primary)
- Indications Acromegaly
- Focus Adverse reactions; Therapeutic Use
- Sponsors Endo Pharmaceuticals
- 13 Nov 2014 New trial record